<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270750</url>
  </required_header>
  <id_info>
    <org_study_id>GHC2/29/22-09-2008</org_study_id>
    <nct_id>NCT01270750</nct_id>
  </id_info>
  <brief_title>Bosentan for Severe Mitral Valve Dysfunction</brief_title>
  <acronym>BOSMIVAR</acronym>
  <official_title>Pilot Trial of Bosentan for Secondary Pulmonary Hypertension Due to Severe Mitral Valve Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Chalkida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Chalkida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoconstrictive signaling via endothelin receptors is not limited to primary pulmonary
      arterial hypertension, but has also been documented in secondary pulmonary hypertension due
      to congestive heart failure, including cardiac valve disease. The investigators aim to
      examine the clinical and physiologic effects of bosentan therapy in patients with secondary
      pulmonary hypertension due to severe, inoperable cardiac valve disease, using a
      single-center, prospective, open-label, non-randomized study of oral bosentan in outpatients
      with severe mitral stenosis due to childhood rheumatoid fever. Primary end-point will be
      exercise capacity at six months determined by six-minute walking distance and cardiopulmonary
      exercise testing. Secondary end-points will be symptomatic relief, echocardiographic left
      ventricular function and pulmonary pressure, serum pro-brain natriuretic peptide, and adverse
      events at six months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SIX MINUTE WALKING DISTANCE</measure>
    <time_frame>SIX MONTHS</time_frame>
    <description>CHANGE IN SIX MINUTE WALKING DISTANCE AFTER 6 MONTHS OF THERAPY COMPARED TO PRE-TREATMENT VALUE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAXIMAL OXYGEN UPTAKE</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>CHANGE IN MAXIMAL OXYGEN UPTAKE AFTER 6 MONTHS OF THERAPY COMPARED TO PRE-TREATMENT VALUE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECHOCARDIOGRAPHIC PULMONARY PRESSURE</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>ECHOCARDIOGRAPHIC ASSESSMENT OF PEAK AND MEAN PULMONARY PRESSURE AT 6 MONTHS AFTER TREATMENT COMPARED WITH PRE-TREATMENT VALUES.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHOCARDIOGRAPHIC LEFT VENTRICULAR FUNCTION</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT VENTRICULAR FUNCTION AT 6 MONTHS AFTER TREATMENT COMPARED WITH PRE-TREATMENT VALUES.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SERUM PRO-BNP</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>ASSESSMENT OF SERUM PRO-BRAIN NATRIURETIC PEPTIDE LEVELS AT 6 MONTHS AFTER TREATMENT COMPARED WITH PRE-TREATMENT VALUES.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DYSPNEA</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>CHANGE IN BORG DYSPNEA INDEX COMPARED WITH PRE-TREATMENT VALUES.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>SECONDARY PULMONARY HYPERTENSION</condition>
  <condition>MITRAL STENOSIS</condition>
  <condition>CHILDHOOD RHEUMATOID FEVER</condition>
  <condition>CONGESTIVE HEART FAILURE</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOSENTAN</intervention_name>
    <description>TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient

          -  &gt; 60 Yrs Old

          -  &lt; 85 Yrs Old

          -  Stable disease

          -  Congestive heart failure NYHA IIIB/V

          -  Inoperable mitral stenosis due to childhood rheumatoid fever

          -  Mean pulmonary artery pressure &gt; 40 cm H2O

        Exclusion Criteria:

          -  Prior treatment with endothelin receptor antagonist(s)

          -  Hospitalization (exacerbation)

          -  Cardiac valve surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GEORGE VLACHOGIORGOS, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GENERAL HOSPITAL OF CHALKIDA, GREECE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GEORGE VLACHOGIORGOS, MD PHD</last_name>
    <phone>00306936192419</phone>
    <email>georgevlacho@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Chalkida</name>
      <address>
        <city>Chalkida</city>
        <state>Evoia</state>
        <zip>34100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GEORGE VLACHOGIORGOS, MD PHD</last_name>
      <phone>00306936192419</phone>
      <email>georgevlacho@gmail.com</email>
    </contact>
    <investigator>
      <last_name>GEORGE VLACHOGIORGOS, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <last_update_submitted>January 27, 2011</last_update_submitted>
  <last_update_submitted_qc>January 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>GEORGE VLACHOGIORGOS</name_title>
    <organization>General Hospital of Chalkida</organization>
  </responsible_party>
  <keyword>ENDOTHELIN RECEPTOR ANTAGONIST</keyword>
  <keyword>BOSENTAN</keyword>
  <keyword>SECONDARY PULMONARY HYPERTENSION</keyword>
  <keyword>RHEUMATOID FEVER</keyword>
  <keyword>CONGESTIVE HEART FAILURE</keyword>
  <keyword>SECONDARY PULMONARY HYPERTENSION DUE TO MITRAL STENOSIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

